These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22562974)

  • 1. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
    Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten RE; Supronik J; Szombati I; Romer U; Witte S; Saag KG
    Ann Rheum Dis; 2013 Feb; 72(2):204-10. PubMed ID: 22562974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Ann Rheum Dis; 2010 Jul; 69(7):1275-80. PubMed ID: 20542963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis.
    Alten R; Grahn A; Holt RJ; Rice P; Buttgereit F
    RMD Open; 2015; 1(1):e000134. PubMed ID: 26535146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
    Buttgereit F; Kent JD; Holt RJ; Grahn AY; Rice P; Alten R; Yazici Y
    Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):168-77. PubMed ID: 26535595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis.
    Ursini F; Naty S; Bruno C; Grembiale RD
    Rev Recent Clin Trials; 2017; 12(2):124-128. PubMed ID: 28356031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified-release prednisone: in patients with rheumatoid arthritis.
    Henness S; Yang LP
    Drugs; 2013 Dec; 73(18):2067-76. PubMed ID: 24249648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.
    Buttgereit F; Strand V; Lee EB; Simon-Campos A; McCabe D; Genet A; Tammara B; Rojo R; Hey-Hadavi J
    RMD Open; 2019; 5(1):e000889. PubMed ID: 31168411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
    Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
    Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
    van Everdingen AA; Jacobs JW; Siewertsz Van Reesema DR; Bijlsma JW
    Ann Intern Med; 2002 Jan; 136(1):1-12. PubMed ID: 11777359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?
    Boers M; Buttgereit F; Saag K; Alten R; Grahn A; Storey D; Rice P; Kirwan J
    Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1202-1209. PubMed ID: 25807939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Lancet; 2008 Jan; 371(9608):205-14. PubMed ID: 18207016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.